PneumoWave

PneumoWave specializes in developing a remote diagnostic and monitoring device using a biosensor technology platform. Its main focus is on preventing serious adverse effects caused by respiratory conditions, with the goal of reducing hospital admissions and preventing deaths. The company offers an end-to-end management solution that integrates machine learning and biology, enabling the detection, monitoring, and prediction of respiratory health conditions. These solutions provide insights for clinicians to personalize virtual care for patients with acute, post-acute, and chronic respiratory conditions.

The company's core offering features a chest-worn wearable biosensor technology that passively captures real-time respiratory data. This approach enables early detection of Chronic Obstructive Pulmonary Disease (COPD) deterioration, enabling prompt intervention and personalized management to improve patient outcomes.

The company's focus areas include addressing Opioid Induced Respiratory Depression, pediatric respiratory conditions, and COPD. The company’s software received FDA Breakthrough designation in October 2021, and, as of May 2024, its technology was under development. 

Key customers and partnerships

The company’s technology platform is being developed with various partners, including clinical trial partners such as the University of Dundee, University of Glasgow, and King’s College London. Its technology partners include Galen Data, Peacock Technology, and Fearsome, among others. Additionally, the company collaborates with organizations like Scottish Enterprise and QARA Consulting, along with other partners.

Funding and financials

In January 2023, the company raised USD 9.1 million (~GBP 7.5 million) in a Series A funding round led by Scottish National Investment Bank, Scottish Enterprise, IIG, Equity Gap, Alba Equity, and Mark Bamforth of Thairm Bio. The funds were used in clinical validation and regulatory filing for its technology platform.